

S C Bain

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1686369/publications.pdf>

Version: 2024-02-01

129
papers

9,030
citations

147726

31
h-index

42364

92
g-index

131
all docs

131
docs citations

131
times ranked

7208
citing authors

#	ARTICLE	IF	CITATIONS
1	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 1834-1844.	13.9	3,898
2	Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019, 381, 841-851.	13.9	1,002
3	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. <i>Lancet</i> , The, 2017, 389, 1399-1409.	6.3	502
4	Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 251-260.	5.5	363
5	Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 355-366.	5.5	288
6	Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 889-897.	2.2	173
7	The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. <i>Diabetes Therapy</i> , 2021, 12, 143-157.	1.2	154
8	A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 3567-3602.	1.1	146
9	Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 454-466.	2.2	129
10	Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 442-451.	2.2	102
11	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2020, 43, 1546-1552.	4.3	92
12	Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. <i>Circulation</i> , 2022, 145, 575-585.	1.6	88
13	Anti-interleukin-21 antibody and liraglutide for the preservation of β -cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 212-224.	5.5	85
14	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. <i>Circulation</i> , 2018, 138, 2884-2894.	1.6	82
15	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease. <i>Circulation</i> , 2018, 137, 2179-2183.	1.6	80
16	The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. <i>Diabetes Care</i> , 2018, 41, 2229-2235.	4.3	74
17	Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 499-508.	2.2	71
18	Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. <i>Cardiovascular Diabetology</i> , 2019, 18, 73.	2.7	69

#	ARTICLE	IF	CITATIONS
19	Large Pre- and Postexercise Rapid-Acting Insulin Reductions Preserve Glycemia and Prevent Early- but Not Late-Onset Hypoglycemia in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2217-2224.	4.3	66
20	A combined insulin reduction and carbohydrate feeding strategy 30 min before running best preserves blood glucose concentration after exercise through improved fuel oxidation in type 1 diabetes mellitus. <i>Journal of Sports Sciences</i> , 2011, 29, 279-289.	1.0	59
21	A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives. <i>Advances in Therapy</i> , 2022, 39, 33-43.	1.3	57
22	Performance of the Freestyle Libre flash glucose monitoring (flash GM) system in individuals with type 1 diabetes: A secondary outcome analysis of a randomized crossover trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2505-2512.	2.2	55
23	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1128-1141.	1.2	53
24	One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 492-500.	1.2	42
25	LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. <i>Cardiovascular Diabetology</i> , 2016, 15, 29.	2.7	42
26	Blood glucose responses to reductions in pre-exercise rapid-acting insulin for 24 h after running in individuals with type 1 diabetes. <i>Journal of Sports Sciences</i> , 2010, 28, 781-788.	1.0	41
27	Occurrence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events. <i>JAMA Cardiology</i> , 2019, 4, 1214.	3.0	39
28	Metabolic Implications when Employing Heavy Pre- and Post-Exercise Rapid-Acting Insulin Reductions to Prevent Hypoglycaemia in Type 1 Diabetes Patients: A Randomised Clinical Trial. <i>PLoS ONE</i> , 2014, 9, e97143.	1.1	38
29	Algorithm that delivers an individualized rapid-acting insulin dose after morning resistance exercise counters post-exercise hyperglycaemia in people with Type 1 diabetes. <i>Diabetic Medicine</i> , 2016, 33, 506-510.	1.2	36
30	Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 611-621.	2.2	35
31	Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. <i>Annals of Internal Medicine</i> , 2019, 170, 423.	2.0	34
32	Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme. <i>Diabetes Therapy</i> , 2020, 11, 259-277.	1.2	34
33	Impact of pre-exercise rapid-acting insulin reductions on ketogenesis following running in Type 1 diabetes. <i>Diabetic Medicine</i> , 2011, 28, 218-222.	1.2	33
34	Recent advances in understanding the role of glucagon-like peptide 1. <i>F1000Research</i> , 2020, 9, 239.	0.8	33
35	Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2487-2492.	2.2	31
36	Similar magnitude of post-exercise hyperglycemia despite manipulating resistance exercise intensity in type 1 diabetes individuals. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2016, 26, 404-412.	1.3	30

#	ARTICLE	IF	CITATIONS
37	Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2021, 44, 1020-1026.	4.3	30
38	Exenatide and pancreatitis: an update. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 643-644.	1.0	29
39	ADP-ribosylation factor 6 regulates endothelin-1-induced lipolysis in adipocytes. <i>Biochemical Pharmacology</i> , 2014, 90, 406-413.	2.0	27
40	Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK. <i>Journal of Medical Economics</i> , 2020, 23, 98-105.	1.0	27
41	The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes. <i>Diabetes Therapy</i> , 2020, 11, 835-844.	1.2	27
42	IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy. <i>Diabetes Therapy</i> , 2015, 6, 573-591.	1.2	26
43	Costs of the COVID-19 pandemic associated with obesity in Europe: A health care cost model. <i>Clinical Obesity</i> , 2021, 11, e12442.	1.1	26
44	Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. <i>Circulation</i> , 2018, 138, 1605-1607.	1.6	25
45	Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. <i>Cardiovascular Diabetology</i> , 2020, 19, 156.	2.7	25
46	Association of British Clinical Diabetologists and Renal Association guidelines on the detection and management of diabetes post solid organ transplantation. <i>Diabetic Medicine</i> , 2021, 38, e14523.	1.2	25
47	The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist. <i>Diabetes Therapy</i> , 2014, 5, 367-383.	1.2	23
48	Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized crossover trial. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 196-199.	2.2	23
49	Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 1157-1166.	2.2	22
50	Effect of structured self-monitoring of blood glucose, with and without additional TeleCare support, on overall glycaemic control in non-insulin treated Type 2 diabetes: the SMBG Study, a 12-month randomized controlled trial. <i>Diabetic Medicine</i> , 2019, 36, 578-590.	1.2	22
51	Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1745-1751.	2.2	22
52	Costs of COVID-19 pandemic associated with diabetes in Europe: a health care cost model. <i>Current Medical Research and Opinion</i> , 2021, 37, 27-36.	0.9	20
53	Changes in Plasma Levels of N-Arachidonoyl Ethanolamine and N-Palmitoylethanolamine following Bariatric Surgery in Morbidly Obese Females with Impaired Glucose Homeostasis. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-8.	1.0	19
54	Heart rate dynamics during cardio-pulmonary exercise testing are associated with glycemic control in individuals with type 1 diabetes. <i>PLoS ONE</i> , 2018, 13, e0194750.	1.1	19

#	ARTICLE	IF	CITATIONS
55	Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 303-314.	2.2	19
56	The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the <sc>LEADER</sc> and <sc>SUSTAIN</sc> 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1690-1695.	2.2	19
57	Omarigliptin for the treatment of type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1947-1952.	0.9	18
58	Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (<sc>SUSTAIN</sc> 6). <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1339-1347.	2.2	18
59	Safety and side effects of the insulin analogues. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 131-143.	1.0	17
60	A multicentre, <sc>UK</sc>, retrospective, observational study to assess the effectiveness of insulin glargine 300 units/ml in treating people with Type 1 diabetes mellitus in routine clinical practice (<sc>SPARTA</sc>). <i>Diabetic Medicine</i> , 2019, 36, 110-119.	1.2	17
61	Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation. <i>PLoS ONE</i> , 2016, 11, e0154229.	1.1	17
62	Extent and prevalence of post-exercise and nocturnal hypoglycemia following peri-exercise bolus insulin adjustments in individuals with type 1 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 227-236.	1.1	16
63	Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study. <i>Diabetes Therapy</i> , 2021, 12, 801-811.	1.2	16
64	Poor glycaemic control is associated with reduced exercise performance and oxygen economy during cardio-pulmonary exercise testing in people with type 1 diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 93.	1.2	14
65	<p></p>Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data<p></p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 433-438.	1.1	13
66	Self-monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes (The SMBG Study): study protocol for a randomised controlled trial. <i>BMC Endocrine Disorders</i> , 2017, 17, 4.	0.9	12
67	Supplementary Nitric Oxide Donors and Exercise as Potential Means to Improve Vascular Health in People with Type 1 Diabetes: Yes to NO?. <i>Nutrients</i> , 2019, 11, 1571.	1.7	12
68	The new NICE guidelines for type 2 diabetes – a critical analysis. <i>British Journal of Diabetes and Vascular Disease</i> , 2015, 15, 3.	0.6	12
69	Ageing well with diabetes: A workshop to co-design research recommendations for improving the diabetes care of older people. <i>Diabetic Medicine</i> , 2022, 39, e14795.	1.2	12
70	Resistance Isn't Futile: The Physiological Basis of the Health Effects of Resistance Exercise in Individuals With Type 1 Diabetes. <i>Frontiers in Endocrinology</i> , 2019, 10, 507.	1.5	11
71	Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the <sc>LEADER</sc> and <sc>SUSTAIN</sc> 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2193-2198.	2.2	11
72	Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the <sc>LEADER</sc> randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2077-2088.	2.2	10

#	ARTICLE	IF	CITATIONS
73	Safety of injectable semaglutide for type 2 diabetes. Expert Opinion on Drug Safety, 2020, 19, 785-798.	1.0	10
74	Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease. Diabetic Medicine, 2022, 39, e14769.	1.2	10
75	Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021. Kidney International Reports, 2022, 7, 681-687.	0.4	10
76	Recent developments in GLP-1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class. Diabetes, Obesity and Metabolism, 2021, 23, 30-39.	2.2	9
77	Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. Diabetes, Obesity and Metabolism, 2019, 21, 2450-2458.	2.2	8
78	Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK. Diabetic Medicine, 2019, 36, 1063-1071.	1.2	8
79	Semaglutide injection for the treatment of adults with type 2 diabetes. Expert Review of Clinical Pharmacology, 2020, 13, 675-684.	1.3	8
80	Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. Cardiovascular Endocrinology, 2018, 7, 18-23.	0.8	7
81	Treatment of Type 2 Diabetes Mellitus With Orally Administered Agents: Advances in Combination Therapy. Endocrine Practice, 2009, 15, 750-762.	1.1	5
82	Diabetes, diabetes therapies and cancer: what's the link?. British Journal of Diabetes and Vascular Disease, 2011, 11, 235-238.	0.6	5
83	A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes. Diabetic Medicine, 2020, 37, 219-228.	1.2	5
84	Clinical experience with liraglutide. International Journal of Clinical Practice, 2010, 64, 44-48.	0.8	4
85	A retrospective observational study of people with Type 1 diabetes with self-reported severe hypoglycaemia reveals high level of ambulance attendance but low levels of therapy change and specialist intervention. Diabetic Medicine, 2018, 35, 1223-1231.	1.2	4
86	Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2018, 12, 1079-1082.	1.8	4
87	EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES â€” A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	4
88	EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) â€” A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	4
89	Delivering joined-up care for people with type 2 diabetes: rationale, challenges and examples. British Journal of Diabetes, 2021, 21, 89-95.	0.1	4
90	Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population-based observational retrospective cohort study. Diabetic Medicine, 2022, 39, e14697.	1.2	4

#	ARTICLE	IF	CITATIONS
91	Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice. <i>Diabetes Therapy</i> , 2022, 13, 225-240.	1.2	4
92	New Therapeutic Horizons in Chronic Kidney Disease: The Role of SGLT2 Inhibitors in Clinical Practice. <i>Drugs</i> , 2022, 82, 97-108.	4.9	4
93	Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6. <i>Cardiovascular Diabetology</i> , 2022, 21, 64.	2.7	4
94	Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity. , 2022, 18, 43.		4
95	FP482EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	3
96	Efficacy of newer agents in the glycaemic management of patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2020, 36, 209-211.	0.9	3
97	Metabolomic, hormonal and physiological responses to hypoglycemia versus euglycemia during exercise in adults with type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001577.	1.2	3
98	Estimands in diabetes clinical trials. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 181-183.	5.5	3
99	One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2021, 12, 1593-1604.	1.2	3
100	A retrospective epidemiological study of Type 1 Diabetes Mellitus in Wales, UK between 2008 and 2018. <i>International Journal of Population Data Science</i> , 2021, 6, 1387.	0.1	3
101	The Cellnovo Insulin Delivery System. <i>European Endocrinology</i> , 2017, 13, 13.	0.8	3
102	Blood Glucose Responses during Cardiopulmonary Incremental Exercise Testing in Type 1 Diabetes: A Pooled Analysis. <i>Medicine and Science in Sports and Exercise</i> , 2021, 53, 1142-1150.	0.2	3
103	Postmarket Approval Surveillance of a Low Acquisition Cost Blood Glucose Monitoring System. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 1195-1196.	1.3	2
104	A case series of DKA occurring in patients receiving treatment with SGLT2 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1800-1801.	2.2	2
105	MO051EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	2
106	TO002REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	2
107	Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. <i>Drugs</i> , 2021, 81, 1243-1255.	4.9	2
108	Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently. <i>Diabetes Therapy</i> , 2022, 13, 889-911.	1.2	2

#	ARTICLE	IF	CITATIONS
109	Basal insulin reductions in anticipation of multiple exercise sessions in people with type 1 diabetes—a clinical perspective. <i>Annals of Translational Medicine</i> , 2018, 6, S111-S111.	0.7	1
110	Pancreatic β -Cell Function Is Associated with Augmented Counterregulation to In-Exercise Hypoglycemia in Type 1 Diabetes. <i>Medicine and Science in Sports and Exercise</i> , 2021, 53, 1326-1333.	0.2	1
111	Complex disease genetics enters the high street. <i>European Journal of Clinical Investigation</i> , 2003, 33, 186-188.	1.7	0
112	Safety and side effects of the insulin analogues. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 349-350.	1.0	0
113	Liraglutide in Combination with Metformin or Sulfonylurea for the Treatment of Type 2 Diabetes in Adult patients. <i>Clinical Medicine Insights Therapeutics</i> , 2012, 4, CMT.S7283.	0.4	0
114	P6271 The effect of semaglutide once weekly on MACE and blood pressure by race and ethnicity: SUSTAIN 6 post hoc analysis. <i>European Heart Journal</i> , 2019, 40, .	1.0	0
115	Clumsy hands in a woman with long-standing diabetes. <i>Diabetic Medicine</i> , 2019, 37, 1770-1771.	1.2	0
116	An unusual finding during retinal screening. <i>Diabetic Medicine</i> , 2020, 37, 1605-1606.	1.2	0
117	Foot deformity in a man with Type 2 diabetes. <i>Diabetic Medicine</i> , 2020, 37, 157-158.	1.2	0
118	An update to: Pharmacological treatment for type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK . <i>Diabet Med</i> 2019; 36: 1063–1071. <i>Diabetic Medicine</i> , 2020, 37, 1405-1407.	1.2	0
119	A slightly itchy rash on the hand of a person with type 1 diabetes. <i>Diabetic Medicine</i> , 2020, 37, 1609-1610.	1.2	0
120	An unusual skin rash in a person with type 1 diabetes. <i>Diabetic Medicine</i> , 2020, 37, 1607-1608.	1.2	0
121	A man with nodules on the backs of his hands. <i>Diabetic Medicine</i> , 2020, 37, 1766-1767.	1.2	0
122	Cover Image, Volume 22, Issue 3. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, .	2.2	0
123	Improved Nocturnal Glycaemia and Reduced Insulin Use Following Clinical Exercise Trial Participation in Individuals With Type 1 Diabetes. <i>Frontiers in Public Health</i> , 2020, 8, 568832.	1.3	0
124	A woman with poorly controlled type 1 diabetes and pruritic papules on her buttocks. <i>Diabetic Medicine</i> , 2021, 38, e14539.	1.2	0
125	Semaglutid reduzierte den HbA1c in allen Subgruppen des Ausgangs-HbA1c (SUSTAIN 1 – 5). <i>Diabetologie Und Stoffwechsel</i> , 2018, 13, .	0.0	0
126	Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme. , 2019, 14, .		0

#	ARTICLE	IF	CITATIONS
127	An elderly woman with scars on her shins. <i>Diabetic Medicine</i> , 2022, 39, e14818.	1.2	0
128	MO462: Change in KDIGO Kidney Risk Category With Semaglutide Treatmentâ€™A <i>Post Hoc</i> Analysis of the Sustain 6 Trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
129	Glucagon-like peptide-1 receptor agonists as anti-inflammatory agents: A potential mode of cardiovascular benefits. <i>Atherosclerosis</i> , 2022, , .	0.4	0